Détail de l'éditeur
Publications Office of the European Union
localisé à :
Luxembourg
|
Documents disponibles chez cet éditeur (150)
Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]Rapport
This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. I[...]Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant [...]Rapport
This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 N[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 No[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1 phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of th[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7[...]Rapport
Based on the options provided by the international drug control legal framework, this paper considers the rehabilitative measures of treating, educating or reintegrating drug users as alternatives or additions to conviction or punishment that ar[...]Rapport
Europol ; L. LANIEL ; C. CARPENTIER ; J. MOUNTENEY ; B. PALLAVICINI ; L. ROYUELA ; J. MATIAS ; R. KASECKER ; R. SEDEFOV ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Joint publications | 2011FRANÇAIS : L'OEDT et Europol publient une analyse conjointe concernant le marché des amphétamines. Leader dans la production des amphétamines, l'Europe est également une zone importante de consommation. ENGLISH: This joint publication with [...]Rapport
This report presents new findings from the ESCAPE (European Syringe Collection and Analysis Project Enterprise) network, based on the chemical analysis of the contents of used syringes across sentinel sites in Europe. Syringes were collected in [...]Rapport
OEDT = EMCDDA ; A. HEINEMANN ; S. IWERSEN-BERGMANN | Lisbon : OEDT / EMCDDA | Technical reports | 2019The objective of this report is to provide an updated analysis of the post-mortem toxicology practices of drug-related deaths (DRD) in Europe and to discuss the effect of these practices on the monitoring of DRDs. It is based on the results of a[...]Rapport
OEDT = EMCDDA ; S. CASTIGLIONI, Éditeur scientifique ; L. VANDAM ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016"Assessing illicit drugs in wastewater: advances in wastewater-based drug epidemiology" reviews a new approach to estimating drug use in populations, based on the detection and quantification of drugs and their metabolic products in community wa[...]Rapport
This report reviews how opioid substitution treatment (OST) is implemented in European countries and examines the public health consequences of the diversion and misuse of prescription OST medications. It looks at how OST medications are diverte[...]Rapport
Being young in Europe today' presents some of Eurostat's most interesting data on children and young people in the European Union. It gives an insight into the past, current and future situation of our youngest fellow citizens, ranging from atte[...]Rapport
This publication answers some of the more frequently asked questions raised in discussions about cannabis legislation. While the primary focus is on the use of cannabis for recreational purposes, relevant legislation for other uses, including me[...]Rapport
At a time of increased debate on the laws controlling the use of cannabis in the European Union, this report answers some of the questions most often asked about cannabis legislation. Using a question and answer format, basic definitions and the[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; M. GANDILHON ; J. E. ADES ; A. CUNNINGHAM ; N. SINGLETON ; R. SEDEFOV ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018Captagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. [...]Rapport
This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2[...]Rapport
D. OLSZEWSKI ; G. BURKHART ; A. BO | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2010The purpose of this paper is to give meaning and insight into some of the key drug and alcohol issues that affect children from the perspectives of the children themselves. It is not to estimate the relative magnitude of a specific drug or alcoh[...]Rapport
OEDT = EMCDDA ; L. MONTANARI ; M. PASINETTI ; D. THANKI ; J. VICENTE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013Identifying the co-occurrence of drug use and mental health disorders in the same individuals is essential for effective treatment of their drug use problems. Reviewing the available information on psychiatric co-morbidity among drug users in Eu[...]Rapport
Community coalitions are a strategy to coordinate activities and resources to prevent adolescent substance use and delinquent behaviour. They can help mobilise communities in prevention and health promotion initiatives. The Communities That Car[...]Rapport
OEDT = EMCDDA ; M. TORRENS ; J. I. MESTRE-PINTO ; A. DOMINGO-SALVANY ; L. MONTANARI ; J. VICENTE | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2015This publication looks at the co-occurrence of drug use problems and mental health disorders, taking in the theoretical background of psychiatric comorbidity, the tools for clinical diagnosis and the prevalence and clinical relevance of the prob[...]Rapport
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017.[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018.[...]Rapport
This paper presents the EMCDDA's current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction - building on the work completed in this area and expanding to reflect the academic research underpinning this [...]Rapport
OEDT = EMCDDA ; T. FREEMAN ; T. GROSHKOVA ; A. CUNNINGHAM ; P. GRIFFITHS ; D. POTTER ; S. CRAFT ; A. ENGLUND ; M. LYNSKEY ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2019ENGLISH: This paper provides an overview of established and emerging cannabis products in Europe. For each type of product, major issues in its production, distribution, use and effects on health are detailed. In doing so, the paper seeks to in[...]Rapport
OEDT = EMCDDA ; H. SCHULZE, Coordonnateur ; M. SCHUMACHER ; R. URMEEW ; K. AUERBACH ; J. ALVAREZ ; I. M. BERNHOFT ; H. DE GIER ; M. HAGENZIEKER ; S. HOUWING ; A. KNOCHE ; B. PILGERSTORFER ; B. ZLENDER ; B. HUGHES ; L. VANDAM | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2012This Thematic paper presents the key findings of the European Union’s research project on Driving Under the Influence of Drugs, Alcohol and Medicines, known as the DRUID project. The project looked at experimental studies, epidemiological studie[...]Rapport
FRANÇAIS : Les peines prononcées à l'encontre des délinquants pour des infractions liées à la drogue à travers l'Union européenne sont examinées pour la première fois dans la présente «Question spécifique». En analysant les statistiques les pl[...]Rapport
OEDT = EMCDDA ; A. O'GORMAN ; E. QUIGLEY ; F. ZOBEL ; K. MOORE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013This study explores the civil society organisations that engage in drug policy advocacy in Europe. An Internet search in English, French and Spanish combined with information from national sources in 30 countries identified 218 organisations act[...]Rapport
This paper describes the development and main characteristics of drug policy in Austria. It traces the development of Austrian drug laws from the time of the Austro-Hungarian Empire through to the present day. Austria's drug policy has several d[...]Rapport
This paper describes the development and main characteristics of drug policy in Poland. It starts with the early days of drug control in Poland in the 1920s, describes the changes related to the emergence of Polish heroin - Kompot - in the late [...]Rapport
OEDT = EMCDDA ; E. QUIGLEY ; B. HUGHES ; C. COSTA STORTI ; F. ZOBEL | Lisbon : OEDT / EMCDDA | Drug policy profiles, ISSN 1977-2246 | 2013The national drug policy of Ireland comes under the spotlight in the second volume in the EMCDDA series of Drug policy profiles. Examining the evolution of Irish drug policy through four periods of historic development, the report explores: the [...]Rapport
This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU. This includes describing the 'pre-precursor' phenomenon and r[...]Rapport
This report considers substance use prevention in Europe through the lens of a system, highlighting the wide range of factors that need to be addressed to successfully implement substance use prevention programmes and policies. They are consider[...]Rapport
This publication provides an update on drug-related deaths in Europe, presenting and analysing the latest data and trends in drug-induced deaths and overall mortality among high-risk drug users in the European Union and beyond. It draws on contr[...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; F. MATHIS ; D. HEDRICH ; J. VICENTE ; A. NOOR | Lisbon : OEDT / EMCDDA | Technical reports | 2021This report provides an update on drug-related deaths in Europe based primarily on presentations and discussions held at the 2019 meeting of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) expert network on drug-related deat[...]Rapport
This report is part of the EMCDDA activity around the development and improvement of drug supply indicators, which are designed to reflect developments in drug markets as well as the markets' wider harms and impact. The protocol in this document[...]Rapport
Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a [...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; A. M. DINES ; N. SINGLETON ; A. NOOR ; P. I. DARGAN ; D. WOOD | Lisbon : OEDT / EMCDDA | Technical reports | 2020ENGLISH: This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of th[...]Rapport
This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while high[...]Rapport
This report presents an overview of infectious diseases among people who inject drugs in Europe, both in the community and in prison settings, covering disease surveillance, outbreak investigations, and prevention and control, for the period up [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe for the period up to June 2015. The report covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; R. KASECKER ; T. GROSHKOVA ; C. CARPENTIER | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013Drug law enforcement activity targets the supply of drugs and is responsible for much of the key data that informs our understanding of drugs supply in Europe. This study looks, for the first time, at how drug law enforcement is organised in Eur[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; T. SURMONT ; T. STOIAN ; S. ALM | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2017In 2014, the EMCDDA took the decision to carry out a limited follow-up study of the EMCDDA Paper Drug squads: units specialised in drug law enforcement in Europe (EMCDDA, 2013), with the aim of monitoring possible changes and trends in drug supp[...]Rapport
OEDT = EMCDDA ; E. QUIGLEY ; R. SEDEFOV ; C. CARPENTIER ; L. LANIEL ; European Commission, COWI Consortium for DG Health and Consumers | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013The production and trafficking of illicit drugs poses complex and interlinked problems, which have a negative impact on public health and the security and stability of society. Focusing on actions directed at the EU's internal security situation[...]Rapport
It is estimated that over 1 million people receive treatment for drug-related problems in the European Union every year. With shrinking public budgets, increasing pressure on health systems, changes in the drugs used and the need to provide on-g[...]Rapport
This report presents a summary of the key findings from drug treatment facility surveys carried out in 2017 in Albania, Bosnia and Herzegovina, Serbia and the territory of Kosovo. The results provide insight into the characteristics and capacity[...]Rapport
The result of the EMCDDA's cooperation with countries in the Western Balkans over many years, this report is the first of its kind. It gives insight into the drug-related problems faced by six countries in the region, through the available data [...]Rapport
OEDT = EMCDDA ; K. SKARUPOVA ; T. NÉFAU ; E. LEFRANÇOIS ; T. SEYLER | Lisbon : OEDT / EMCDDA | Rapid communication | 2019This report presents the results of an innovative method for gathering information on the substances used by people who inject drugs. In this pilot study, chemical analysis of the contents of used syringes collected from exchange sites reveals t[...]Rapport
FRANÇAIS : Les problèmes liés à la drogue apparaissent souvent - et sont ressentis de la façon la plus aiguë - dans les environnements urbains, ce qui fait des villes d'Europe une précieuse fenêtre d'observation sur les nouvelles tendances du p[...]Rapport
OEDT = EMCDDA ; A. GALLEGOS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2012This publication presents 30 profiles of the national early warning systems on new psychoactive substances in operation in Europe in 2011. The early warning system on new psychoactive substances is a multidisciplinary network consisting of 30 Eu[...]Congrès
The conference "Identifying Europes information needs for effective drug policy" marked the 15th anniversary of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and our activity of monitoring drugs and drug addiction in the [...]Rapport
In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been [...]Rapport
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as alpha-pyrrolidinovalerophenone (alpha-PVP), through a joint assessment. The two org[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation '25I-NBOMe', submitted in December 2013 to the Council of the EU, the European Commission an[...]Rapport
In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4′-DMAR). The two organisations concluded th[...]Rapport
At the end of September 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation '5-IT'), through a joint assessment. The two organisations conclu[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and sub[...]Rapport
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]Rapport
This paper is part of the EMCDDA activity around the development and improvement of drug supply indicators, with a focus on drug-related homicide. It builds upon the 2017 review of the academic research and data sources on drug-related homicide [...]Rapport
Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an emergency department ma[...]Rapport
OEDT = EMCDDA ; D. MANSFIELD ; A. CUNNINGHAM ; L. LANIEL ; P. GRIFFITHS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2020This paper provides an analysis of the available data that suggest that a methamphetamine industry is rapidly being established in Afghanistan. The analysis provided is based on information from key informants, documentary sources and the analys[...]Rapport
FRANÇAIS : L'usage de tabac et d'alcool chez les élèves de 15 à 16 ans donne des signes de déclin, mais la consommation potentiellement problématique de cannabis et les difficultés posées par les nouvelles conduites addictives soulèvent des in[...]Rapport
This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European level was made.Rapport
This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA.Rapport
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the ma[...]Rapport
The EU SOCTA 2021 is the outcome of a detailed analysis of the threat of serious and organised crime facing the EU, providing information for practitioners, decision-makers and the wider public. As a threat assessment, the SOCTA is a forward-loo[...]Rapport
This Manual is a joint production by the EMCDDA and the Prevention Standards Partnership, and presents and describes basic and expert level quality standards for drug prevention. The standards cover all aspects of drug prevention work, including[...]Rapport
The aim of this 'quick guide' is to make practical information on prevention quality standards available outside the European Union. A condensed version of EMCDDA Manual 7, it includes a description of the eight stages involved in the drug preve[...]Document multimédia
FRANÇAIS : La diversification de l'offre et de l'usage de drogues crée de nouvelles problématiques pour la politique en matière de drogue, de soins et de santé en Europe. [...] Ce rapport fournit la dernière vue d'ensemble existante de la situa[...]Rapport
ENGLISH: This handbook has been developed with the primary purpose of providing specific reference material for the European Prevention Curriculum (EUPC) training courses. It also serves to provide a more general introduction to prevention scie[...]Rapport
OEDT = EMCDDA ; T. NÉFAU ; E. LEFRANÇOIS ; V. DETREZ ; T. SEYLER ; B. GUARITA ; ESCAPE Network | Lisbon : OEDT / EMCDDA | Technical reports | 2021This protocol documents a new approach that has been developed to monitor substances injected by people who inject drugs through analytically confirmed data at the local level: the analysis of residual content of used syringes. Used syringes con[...]Rapport
This document summarises the main issues concerning evaluation in the field of drug policy. Aimed at those managing rather than undertaking drug policy evaluations, the guide acts as an introduction, providing links to the wider literature. Reco[...]Rapport
T. FRIIS SOGAARD ; M. HOJLUND BRAEMER ; M. MULBJERG PEDERSEN | Lisbon : OEDT / EMCDDA | Technical reports | 2021This report provides an analysis of current drug supply models and the related violence and exploitation of vulnerable groups in Denmark. Recent years have seen a growth in criminals' exploitation of vulnerable groups for drug-related crimes. Th[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; T. GROSHKOVA ; D. THANKI ; A. CUNNINGHAM ; M. RYCHERT | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014Concerns about the availability and use of methamphetamine in Europe have been growing for some time. Historically, the use of methamphetamine has been confined largely to the Czech Republic and Slovakia; however, recent signs of the spread of m[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; S. SOLA ; A. ALMEIDA ; R. JORGE ; J. DE MORAIS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2018In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. This report cov[...]Rapport
OEDT = EMCDDA ; C. COSTA STORTI ; D. FRASQUILHO ; G. BURKHART ; M. MOREIRA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014The economic crisis that Europe experienced in 2008 and later presented a grave challenge to public finances. Countries responded to this by undertaking fiscal consolidation. By examining public expenditure in the areas where most drug-related a[...]Congrès
First European conference on drug supply indicators (20-22 October 2010; Brussels, Belgium) | Lisbon : OEDT / EMCDDA | Conference proceedings | 2010The conference was organised around three main thematic areas: the drug market, the drug-crime nexus, and drug supply reduction. In practical terms, the conference provided an opportunity to assess the current state of the art in data availabili[...]Rapport
Rapport
In November 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide, commonly known as furanylfentanyl, through a joint assessment. Furanylf[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the ba[...]Rapport
F. TRAUTMANN ; B. KILMER ; P. TURNBULL | Bruxelles : Commission européenne, Direction générale justice et affaires intérieures, Coordination de la lutte anti-drogue | 2013Highlights [Extracts]: * Our estimates for the EU cannabis market suggest a range of approximately €7 billion to €10 billion for 2010. These estimates are likely low as they do not account for the "consumption gap" that is created when data fro[...]Rapport
Infectious diseases are among the most serious health consequences of injecting drug use and can lead to significant healthcare costs. Injecting drug users are vulnerable to a range of infectious and communicable diseases through a variety of ri[...]Rapport
OEDT = EMCDDA ; C. KROGER ; H. WINTER ; R. SHAW ; L. LEONE | Lisbon : OEDT / EMCDDA | Manuals | 2012The EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe. These guidelines[...]Rapport
FRANÇAIS : Comment répondre aux problèmes des héroïnomanes âgés ? Comment lutter contre les décès causés par le fentanyl et ses dérivés extrêmement puissants ? Comment prévenir les risques dus à la consommation d'alcool et de drogues lors des f[...]Rapport
OEDT = EMCDDA ; A. PIRONA ; A. ATKINSON ; H. SUMNALL | Lisbon : OEDT / EMCDDA | Rapid communication | 2016FRANÇAIS : Bien que l'usage de NPS en Europe demeure relativement faible, l'EMCDDA s'alarme des risques liés à la consommation de ces substances. Les données récentes mettent en évidence que les NPS sont à l'origine d'urgences hospitalières et [...]Rapport
This report provides an overview of principles of effective health risk communication for a drug checking service audience. The contents of this report are based on the findings of international evidence reviews of health risk communication, com[...]Rapport
OEDT = EMCDDA ; M. HICKMAN, Éditeur scientifique ; N. K. MARTIN, Éditeur scientifique ; I. GIRAUDON ; L. WIESSING ; D. HEDRICH ; E. KALAMARA ; P. GRIFFITHS ; R. SIMON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016FRANÇAIS : L'hépatite C est une maladie infectieuse du foie causée par le virus de l'hépatite C (VHC) qui peut être transmis par le sang. Environ 115 millions de personnes à travers le monde ont été infectées à un moment donné de leur vie par l[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; M. RUIZ ; A. BO ; T. GROSHKOVA ; J. MATIAS ; L. VANDAM ; F. CARDOSO ; R. CHRISTIE ; L. MONTANARI ; I. GIRAUDON ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2017This report provides a first look at the emergence of more problematic forms of use of new psychoactive substances among a range of demographic groups, including opioid and amphetamine injectors, prisoners, the homeless and men who have sex with[...]Rapport
FRANÇAIS : Les données des services d'urgences hospitalières montrent que, chaque année, en Europe, des milliers de personnes subissent des empoisonnements et autres problèmes liés aux drogues qui nécessitent une forme d'assistance médicale. Da[...]Rapport
Contingency management (CM) is a general behavioural intervention technique used in the treatment of drug dependence to systematically arrange consequences and it is designed to weaken drug use and strengthen abstinence. The main elements of CM[...]Rapport
This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those re[...]Rapport
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council c[...]